Nour Bouji1, Sijin Wen2, Matthew J Dietz1. 1. Department of Orthopaedics, School of Medicine, West Virginia University, Morgantown, WV 26506, USA. 2. Department of Epidemiology and BioStatistics, School of Public Health, West Virginia University, Morgantown, WV 26506, USA.
Abstract
Introduction: Long antibiotic courses, including intravenous (IV) and oral administrations, are utilized in prosthetic joint infection (PJI) treatment. This meta-analysis examines the non-inferiority of short courses ( < 4 weeks) of IV antibiotics compared to long courses in treating PJI. Critical review of IV treatment is necessary due to the clinical, physical, and financial burden associated with it and its continued prolonged use in the US without much evidence to support the practice. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), databases were searched using predefined medical subject headings (MeSH). Results: The nine included studies reported 521 total hip arthroplasties (THAs) and 530 total knee arthroplasties (TKAs). There was no significant difference in the overall success rate in short- vs. long-duration IV antibiotics for PJI treatment: odds ratio (OR) of 1.65, 95 % confidence interval (CI) of 0.78-3.46, and p = 0 .18. However, due to the moderate to high heterogeneity ( I 2 = 68 %, p < 0.01) amongst studies, an adjusted success rate was calculated after the exclusion of two studies. This showed a statistically significant difference between both groups (OR of 2.45, 95 % CI of 1.21-4.96, p < 0.001) favoring a short course of antibiotics and reflecting a more homogenous population ( I 2 = 51 %, p = 0 .06). Conclusion: This study highlights the limited data available for evaluating IV antibiotic duration in the setting of PJI. We found that a shorter duration of IV antibiotics was non-inferior to a longer duration, with an improved OR of 2.45 for treatment success, likely shortening inpatient stay as well as lessening side effects and antimicrobial resistance with a lower cost to patients and overall healthcare. Copyright:
Introduction: Long antibiotic courses, including intravenous (IV) and oral administrations, are utilized in prosthetic joint infection (PJI) treatment. This meta-analysis examines the non-inferiority of short courses ( < 4 weeks) of IV antibiotics compared to long courses in treating PJI. Critical review of IV treatment is necessary due to the clinical, physical, and financial burden associated with it and its continued prolonged use in the US without much evidence to support the practice. Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), databases were searched using predefined medical subject headings (MeSH). Results: The nine included studies reported 521 total hip arthroplasties (THAs) and 530 total knee arthroplasties (TKAs). There was no significant difference in the overall success rate in short- vs. long-duration IV antibiotics for PJI treatment: odds ratio (OR) of 1.65, 95 % confidence interval (CI) of 0.78-3.46, and p = 0 .18. However, due to the moderate to high heterogeneity ( I 2 = 68 %, p < 0.01) amongst studies, an adjusted success rate was calculated after the exclusion of two studies. This showed a statistically significant difference between both groups (OR of 2.45, 95 % CI of 1.21-4.96, p < 0.001) favoring a short course of antibiotics and reflecting a more homogenous population ( I 2 = 51 %, p = 0 .06). Conclusion: This study highlights the limited data available for evaluating IV antibiotic duration in the setting of PJI. We found that a shorter duration of IV antibiotics was non-inferior to a longer duration, with an improved OR of 2.45 for treatment success, likely shortening inpatient stay as well as lessening side effects and antimicrobial resistance with a lower cost to patients and overall healthcare. Copyright:
Authors: Yale A Fillingham; Craig J Della Valle; Linda I Suleiman; Bryan D Springer; Thorsten Gehrke; Stefano A Bini; John Segreti; Antonia F Chen; Karan Goswami; Timothy L Tan; Noam Shohat; Claudio Diaz-Ledezma; Adam J Schwartz; Javad Parvizi Journal: J Bone Joint Surg Am Date: 2019-07-17 Impact factor: 5.284
Authors: Ho-Kwong Li; Ines Rombach; Rhea Zambellas; A Sarah Walker; Martin A McNally; Bridget L Atkins; Benjamin A Lipsky; Harriet C Hughes; Deepa Bose; Michelle Kümin; Claire Scarborough; Philippa C Matthews; Andrew J Brent; Jose Lomas; Roger Gundle; Mark Rogers; Adrian Taylor; Brian Angus; Ivor Byren; Anthony R Berendt; Simon Warren; Fiona E Fitzgerald; Damien J F Mack; Susan Hopkins; Jonathan Folb; Helen E Reynolds; Elinor Moore; Jocelyn Marshall; Neil Jenkins; Christopher E Moran; Andrew F Woodhouse; Samantha Stafford; R Andrew Seaton; Claire Vallance; Carolyn J Hemsley; Karen Bisnauthsing; Jonathan A T Sandoe; Ila Aggarwal; Simon C Ellis; Deborah J Bunn; Rebecca K Sutherland; Gavin Barlow; Cushla Cooper; Claudia Geue; Nicola McMeekin; Andrew H Briggs; Parham Sendi; Elham Khatamzas; Tri Wangrangsimakul; T H Nicholas Wong; Lucinda K Barrett; Abtin Alvand; C Fraser Old; Jennifer Bostock; John Paul; Graham Cooke; Guy E Thwaites; Philip Bejon; Matthew Scarborough Journal: N Engl J Med Date: 2019-01-31 Impact factor: 91.245
Authors: Maximilian Schindler; Louis Bernard; Wilson Belaieff; Axel Gamulin; Guillaume Racloz; Stéphane Emonet; Daniel Lew; Pierre Hoffmeyer; Ilker Uçkay Journal: J Infect Date: 2013-07-12 Impact factor: 6.072
Authors: Conan MacDougall; J Patrick Powell; Christopher K Johnson; Michael B Edmond; Ronald E Polk Journal: Clin Infect Dis Date: 2005-06-28 Impact factor: 9.079
Authors: M M Pettigrew; J Kwon; J F Gent; Y Kong; M Wade; D J Williams; C B Creech; S Evans; Q Pan; E B Walter; J M Martin; J S Gerber; J G Newland; M E Hofto; M A Staat; V G Fowler; H F Chambers; W C Huskins Journal: mBio Date: 2022-03-24 Impact factor: 7.786